Cargando…

Associations of Renin‐Angiotensin System Antagonist Medication Adherence and Economic Outcomes Among Commercially Insured US Adults: A Retrospective Cohort Study

BACKGROUND: Medication non‐adherence can result in considerable morbidity, mortality, and costs. The Pharmacy Quality Alliance hypertension medication adherence measure is used by US healthcare payers and providers to assess renin‐angiotensin system antagonist medication adherence. However, associat...

Descripción completa

Detalles Bibliográficos
Autores principales: Campbell, Patrick J., Axon, David R., Taylor, Ann M., Pickering, Matthew, Black, Heather, Warholak, Terri, Chinthammit, Chanadda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7660763/
https://www.ncbi.nlm.nih.gov/pubmed/32844732
http://dx.doi.org/10.1161/JAHA.119.016094
_version_ 1783609076050034688
author Campbell, Patrick J.
Axon, David R.
Taylor, Ann M.
Pickering, Matthew
Black, Heather
Warholak, Terri
Chinthammit, Chanadda
author_facet Campbell, Patrick J.
Axon, David R.
Taylor, Ann M.
Pickering, Matthew
Black, Heather
Warholak, Terri
Chinthammit, Chanadda
author_sort Campbell, Patrick J.
collection PubMed
description BACKGROUND: Medication non‐adherence can result in considerable morbidity, mortality, and costs. The Pharmacy Quality Alliance hypertension medication adherence measure is used by US healthcare payers and providers to assess renin‐angiotensin system antagonist medication adherence. However, associations between renin‐angiotensin system antagonist adherence as calculated in quality measures, and healthcare service use and expenditure in commercial populations over a 1‐year timeframe has not been assessed. METHODS AND RESULTS: This retrospective cohort study used eligible commercially insured individuals from the Truven Health MarketScan Commercial Claims and Encounters Research Databases (2009–2015). Generalized linear models with log link and gamma distribution (expenditure) or negative binomial distribution (usage) assessed relationships between hypertension adherence (≥80% proportion of days covered) and healthcare use and expenditures (in 2015 US dollars) while adjusting for covariates (age, sex, geographic region; health plan; Deyo‐Charlson Comorbidity Index, number of chronic medications, and treatment naivety). Beta coefficients were used to compute cost ratios and rate ratios. A total of 4 842 058 subjects were eligible; of those, 3 310 360 (68%) were adherent (adherent mean age 53.3±8.0 years, 55.9% men; non‐adherent mean age 50.3±9.1 years, 53.1% men). Adherence was associated with fewer inpatient (rate ratios, 0.612; 95% CI, 0.607–0.617) and outpatient visits (rate ratios, 0.995; 95% CI, 0.994–0.997); and lower total costs (cost ratios, 0.876; 95% CI, 0.874–0.878) compared with non‐adherence. Adherence was associated with lower average per member per month total costs ($97.98) compared with non‐adherence. CONCLUSIONS: Adherence to renin‐angiotensin system antagonists was associated with fewer outpatient and inpatient visits, and lower total costs compared with non‐adherence in a 1‐year time frame.
format Online
Article
Text
id pubmed-7660763
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-76607632020-11-17 Associations of Renin‐Angiotensin System Antagonist Medication Adherence and Economic Outcomes Among Commercially Insured US Adults: A Retrospective Cohort Study Campbell, Patrick J. Axon, David R. Taylor, Ann M. Pickering, Matthew Black, Heather Warholak, Terri Chinthammit, Chanadda J Am Heart Assoc Original Research BACKGROUND: Medication non‐adherence can result in considerable morbidity, mortality, and costs. The Pharmacy Quality Alliance hypertension medication adherence measure is used by US healthcare payers and providers to assess renin‐angiotensin system antagonist medication adherence. However, associations between renin‐angiotensin system antagonist adherence as calculated in quality measures, and healthcare service use and expenditure in commercial populations over a 1‐year timeframe has not been assessed. METHODS AND RESULTS: This retrospective cohort study used eligible commercially insured individuals from the Truven Health MarketScan Commercial Claims and Encounters Research Databases (2009–2015). Generalized linear models with log link and gamma distribution (expenditure) or negative binomial distribution (usage) assessed relationships between hypertension adherence (≥80% proportion of days covered) and healthcare use and expenditures (in 2015 US dollars) while adjusting for covariates (age, sex, geographic region; health plan; Deyo‐Charlson Comorbidity Index, number of chronic medications, and treatment naivety). Beta coefficients were used to compute cost ratios and rate ratios. A total of 4 842 058 subjects were eligible; of those, 3 310 360 (68%) were adherent (adherent mean age 53.3±8.0 years, 55.9% men; non‐adherent mean age 50.3±9.1 years, 53.1% men). Adherence was associated with fewer inpatient (rate ratios, 0.612; 95% CI, 0.607–0.617) and outpatient visits (rate ratios, 0.995; 95% CI, 0.994–0.997); and lower total costs (cost ratios, 0.876; 95% CI, 0.874–0.878) compared with non‐adherence. Adherence was associated with lower average per member per month total costs ($97.98) compared with non‐adherence. CONCLUSIONS: Adherence to renin‐angiotensin system antagonists was associated with fewer outpatient and inpatient visits, and lower total costs compared with non‐adherence in a 1‐year time frame. John Wiley and Sons Inc. 2020-08-26 /pmc/articles/PMC7660763/ /pubmed/32844732 http://dx.doi.org/10.1161/JAHA.119.016094 Text en © 2020 The Authors, Merck Sharp Inc. and Dohme Corp Inc. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Research
Campbell, Patrick J.
Axon, David R.
Taylor, Ann M.
Pickering, Matthew
Black, Heather
Warholak, Terri
Chinthammit, Chanadda
Associations of Renin‐Angiotensin System Antagonist Medication Adherence and Economic Outcomes Among Commercially Insured US Adults: A Retrospective Cohort Study
title Associations of Renin‐Angiotensin System Antagonist Medication Adherence and Economic Outcomes Among Commercially Insured US Adults: A Retrospective Cohort Study
title_full Associations of Renin‐Angiotensin System Antagonist Medication Adherence and Economic Outcomes Among Commercially Insured US Adults: A Retrospective Cohort Study
title_fullStr Associations of Renin‐Angiotensin System Antagonist Medication Adherence and Economic Outcomes Among Commercially Insured US Adults: A Retrospective Cohort Study
title_full_unstemmed Associations of Renin‐Angiotensin System Antagonist Medication Adherence and Economic Outcomes Among Commercially Insured US Adults: A Retrospective Cohort Study
title_short Associations of Renin‐Angiotensin System Antagonist Medication Adherence and Economic Outcomes Among Commercially Insured US Adults: A Retrospective Cohort Study
title_sort associations of renin‐angiotensin system antagonist medication adherence and economic outcomes among commercially insured us adults: a retrospective cohort study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7660763/
https://www.ncbi.nlm.nih.gov/pubmed/32844732
http://dx.doi.org/10.1161/JAHA.119.016094
work_keys_str_mv AT campbellpatrickj associationsofreninangiotensinsystemantagonistmedicationadherenceandeconomicoutcomesamongcommerciallyinsuredusadultsaretrospectivecohortstudy
AT axondavidr associationsofreninangiotensinsystemantagonistmedicationadherenceandeconomicoutcomesamongcommerciallyinsuredusadultsaretrospectivecohortstudy
AT taylorannm associationsofreninangiotensinsystemantagonistmedicationadherenceandeconomicoutcomesamongcommerciallyinsuredusadultsaretrospectivecohortstudy
AT pickeringmatthew associationsofreninangiotensinsystemantagonistmedicationadherenceandeconomicoutcomesamongcommerciallyinsuredusadultsaretrospectivecohortstudy
AT blackheather associationsofreninangiotensinsystemantagonistmedicationadherenceandeconomicoutcomesamongcommerciallyinsuredusadultsaretrospectivecohortstudy
AT warholakterri associationsofreninangiotensinsystemantagonistmedicationadherenceandeconomicoutcomesamongcommerciallyinsuredusadultsaretrospectivecohortstudy
AT chinthammitchanadda associationsofreninangiotensinsystemantagonistmedicationadherenceandeconomicoutcomesamongcommerciallyinsuredusadultsaretrospectivecohortstudy